News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
333,660 Results
Type
Article (20067)
Company Profile (128)
Press Release (313465)
Multimedia
Podcasts (71)
Webinars (11)
Section
Business (105434)
Career Advice (879)
Deals (18537)
Drug Delivery (97)
Drug Development (50805)
Employer Resources (79)
FDA (7699)
Job Trends (7748)
News (185976)
Policy (17354)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (5)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (4)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (736)
Accelerated approval (3)
Adcomms (17)
Allergies (40)
Alliances (27864)
ALS (54)
Alzheimer's disease (640)
Antibody-drug conjugate (ADC) (89)
Approvals (7709)
Artificial intelligence (140)
Autoimmune disease (15)
Automation (5)
Bankruptcy (177)
Best Places to Work (5553)
BIOSECURE Act (13)
Biosimilars (97)
Biotechnology (57)
Bladder cancer (31)
Brain cancer (19)
Breast cancer (109)
Cancer (1048)
Cardiovascular disease (113)
Career advice (712)
Career pathing (20)
CAR-T (55)
Cell therapy (151)
Cervical cancer (5)
Clinical research (42691)
Collaboration (462)
Compensation (170)
Complete response letters (23)
COVID-19 (1099)
CRISPR (22)
C-suite (146)
Cystic fibrosis (58)
Data (1117)
Decentralized trials (2)
Denatured (18)
Depression (24)
Diabetes (139)
Diagnostics (1809)
Digital health (5)
Diversity (7)
Diversity, equity & inclusion (21)
Drug discovery (81)
Drug pricing (109)
Drug shortages (30)
Duchenne muscular dystrophy (60)
Earnings (39043)
Editorial (32)
Employer branding (10)
Employer resources (73)
Events (48600)
Executive appointments (447)
FDA (8282)
Featured Employer (23)
Friedreich's ataxia (3)
Frontotemporal dementia (1)
Funding (313)
Gene editing (47)
Generative AI (18)
Gene therapy (144)
GLP-1 (594)
Government (1854)
Grass and pollen (2)
Guidances (19)
Healthcare (5908)
Huntington's disease (13)
IgA nephropathy (20)
Immunology and inflammation (85)
Indications (17)
Infectious disease (1180)
Inflammatory bowel disease (82)
Inflation Reduction Act (8)
Influenza (25)
Intellectual property (56)
Interviews (116)
IPO (7369)
IRA (45)
Job creations (2432)
Job search strategy (648)
Kidney cancer (7)
Labor market (22)
Layoffs (278)
Leadership (14)
Legal (4119)
Liver cancer (31)
Lung cancer (159)
Lymphoma (85)
Machine learning (2)
Management (30)
Manufacturing (201)
MASH (49)
Medical device (1966)
Medtech (1969)
Mergers & acquisitions (11426)
Metabolic disorders (494)
Multiple sclerosis (48)
NASH (20)
Neurodegenerative disease (49)
Neuropsychiatric disorders (20)
Neuroscience (951)
NextGen: Class of 2025 (2358)
Non-profit (909)
Northern California (1069)
Now hiring (21)
Obesity (311)
Opinion (190)
Ovarian cancer (33)
Pain (66)
Pancreatic cancer (36)
Parkinson's disease (86)
Partnered (11)
Patents (142)
Patient recruitment (45)
Peanut (16)
People (33472)
Pharmaceutical (74)
Pharmacy benefit managers (21)
Phase I (13370)
Phase II (18056)
Phase III (14508)
Pipeline (714)
Policy (121)
Postmarket research (1618)
Preclinical (4662)
Press Release (29)
Prostate cancer (60)
Psychedelics (16)
Radiopharmaceuticals (161)
Rare diseases (244)
Real estate (3177)
Recruiting (29)
Regulatory (12535)
Reports (22)
Research institute (820)
Resumes & cover letters (138)
Rett syndrome (1)
RNA editing (2)
RSV (25)
Schizophrenia (59)
Series A (57)
Series B (33)
Service/supplier (7)
Sickle cell disease (36)
Southern California (1025)
Special edition (15)
Spinal muscular atrophy (111)
Sponsored (12)
Startups (2009)
State (2)
Stomach cancer (9)
Supply chain (54)
Tariffs (29)
The Weekly (51)
United States (10083)
Vaccines (270)
Venture capitalists (28)
Weight loss (241)
Women's health (14)
Worklife (7)
Date
Last 7 days (239)
Last 30 days (1134)
Last 365 days (16696)
2025 (4818)
2024 (17674)
2023 (19639)
2022 (25874)
2021 (26643)
2020 (24876)
2019 (20063)
2018 (15594)
2017 (17258)
2016 (16208)
2015 (18804)
2014 (14793)
2013 (12556)
2012 (13486)
2011 (13823)
2010 (12739)
Location
Africa (409)
Alabama (23)
Alaska (1)
Arizona (65)
Arkansas (8)
Asia (24952)
Australia (3221)
California (2508)
Canada (1100)
China (325)
Colorado (96)
Connecticut (99)
Delaware (69)
Europe (51416)
Florida (438)
Georgia (55)
Idaho (16)
Illinois (249)
India (20)
Indiana (173)
Iowa (3)
Japan (118)
Kansas (62)
Kentucky (17)
Louisiana (2)
Maine (4)
Maryland (365)
Massachusetts (2122)
Michigan (48)
Minnesota (137)
Mississippi (1)
Missouri (27)
Montana (10)
Nebraska (11)
Nevada (17)
New Hampshire (8)
New Jersey (1028)
New Mexico (21)
New York (737)
North Carolina (496)
North Dakota (2)
Northern California (1069)
Ohio (81)
Oklahoma (5)
Oregon (21)
Pennsylvania (599)
Puerto Rico (11)
Rhode Island (17)
South America (608)
South Carolina (3)
Southern California (1025)
Tennessee (38)
Texas (332)
Utah (54)
Virginia (82)
Washington D.C. (43)
Washington State (216)
Wisconsin (20)
333,660 Results for "sichuan kelun pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Clinical research results for Kelun-Biotech’s TROP2 ADC sacituzumab tirumotecan (sac-TMT) published in Nature Medicine, a top international medical journal
April 13, 2025
·
5 min read
Press Releases
Kelun-Biotech’s Radionuclide-Drug Conjugate (RDC) SKB107 Receives NMPA Approval For The Treatment of Bone Metastases in Solid Tumors
March 26, 2025
·
3 min read
Press Releases
Kelun-Biotech’s TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) Approved for Marketing in Second Indication by NMPA for EGFRm NSCLC
March 10, 2025
·
5 min read
Press Releases
Study Results Abstracts From Kelun-Biotech’s TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) At 2025 ASCO Genitourinary Cancers Symposium
February 13, 2025
·
5 min read
Press Releases
Kelun-Biotech’s Product Tagitanlimab Approved for Marketing in Second Indication in Combination with Cisplatin and Gemcitabine For the First-line Treatment of Patients with recurrent or metastatic NPC
January 23, 2025
·
3 min read
Biotech Bay
CEO of Kelun-Biotech Dr. Micheal Ge delivered a presentation on The 42nd JPM Annual Healthcare Conference
The 42nd J.P. Morgan Annual Healthcare Conference 2024 is taking place on January 8-11 at San Fracisco, USA, members of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. senior management team participated in the conference.
January 11, 2024
·
3 min read
Press Releases
Kelun-Biotech Announce Exclusive License Agreement For SKB378/HBM9378, an Anti-thymic Stromal Lymphopoietin (TSLP) Monoclonal Antibody (mAb).
January 13, 2025
·
4 min read
Drug Development
AACR: Merck, Kelun’s Anti-TROP2 ADC Shows Early Promise in Gastric Cancer
Merck and Kelun-Biotech’s antibody-drug conjugate achieved a 22% objective response rate and 80.5% disease control rate in heavily pretreated patients with gastric or gastroesophageal junction cancer.
April 10, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Kelun-Biotech’s TROP2 ADC Sacituzumab tirumotecan (sac-TMT) Approved For Marketing By NMPA Of China For 2L+ Advanced or Metastatic TNBC
November 27, 2024
·
5 min read
Government
Trump Tariffs Miss Pharma For Now, But Uncertainties Loom
Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector-specific duties “in the next month or so.”
April 3, 2025
·
2 min read
·
Tristan Manalac
1 of 33,366
Next
